“The nation may have finally met a drug it cannot afford”

While there are numerous costly medications, the case of the new Hepatitis C drug from Gilead may finally be the straw that breaks the camel’s back. There is mounting pressure from payers, providers, patients and politicians and even the World Health Organization to reduce the cost of new treatments for Hepatitis C.